XXII is a series a startup based in United States. 1 investor tracked on Brouky Intelligence. Data sourced from Brouky Intelligence.
About
XXII, also known as 22nd Century Group, is a plant biotechnology company focused on tobacco harm reduction and cannabis research. They develop technologies to reduce nicotine in tobacco and modify cannabinoid profiles in cannabis.
Stage
series-a
Investors
1
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky